ClinicalTrials.gg
RecruitingNCT06637332DAPTO-SNAPUpdated Sep 9, 2026

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

A Phase 4 interventional study of Daptomycin for Injection and Vancomycin (IV) in Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia and S. Aureus Bacteremia, sponsored by Todd C. Lee MD MPH FIDSA. Recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Todd C. Lee MD MPH FIDSA · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing daptomycin in Bacteremia — 2 open to participants now, 2 under way, none of them phase 3. Daptomycin · Bacteremia.

Planned enrollment
Largest of 13
300 · median 38
Started
2024
the only one that year
Phase 4
6 of 14
2 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
Todd C. Lee MD MPH FIDSA

Among the 14 studies testing daptomycin in Bacteremia, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 4, and was the 13th registered.

Bacteremia

298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.

Browse Bacteremia studies →

Open to participants now

2 of the 14 studies testing daptomycin in Bacteremia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About daptomycin

Daptomycin: first FDA approval 2003 (CUBICIN), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Bacteremia studies recruiting now, 31 (79%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing daptomycin in Bacteremia, or all of them as a file.
02

Study summary

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

03

Conditions studied

  • Staphylococcus Aureus Septicemia
  • Staphylococcus Aureus Bacteremia
  • S. Aureus Bacteremia
  • S. Aureus Bloodstream Infection
  • Staphylococcus Aureus Endocarditis

Keywords

  • S. aureus bacteremia
  • Methicllin resistant
  • MRSA
  • S. aureus bloodstream infection
  • Daptomycin
  • Vancomycin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion criteria

Inclusion Criteria:

  • Methicillin-resistant S. aureus bacteremia

Exclusion criteria

Exclusion Criteria:

  • Severe allergy or non-severe rash to vancomycin or daptomycin
  • Suspected or confirmed MRSA pneumonia
  • Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Daptomycin

    Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg

    Drug: Daptomycin for Injection

  • Active comparator
    Vancomycin

    Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target

    Drug: Vancomycin (IV)

Interventions

  • DrugDaptomycinStudies of DaptomycinDaptomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg

  • DrugVancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care

06

What researchers measure

Primary outcomes

  1. Desirability of Outcome Ranking (DOOR)

    Desirability of Outcome Ranking (DOOR) - an ordinal outcome with 5 levels defined: Rank 1 - Alive without complication Rank 2 - Alive with 1 complication Rank 3 - Alive with 2 complications Rank 4 - Alive with 3 complications Rank 5 - Dead Complications include: 1. Clinical failure: Absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated. 2. Infectious Complications: Including new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures; change of therapy due to inadequate clinical response. 3. Serious adverse drug event (Common Terminology Criteria class 4) due to study drug OR adverse drug event (classes 1-3) leading to discontinuation of the study drug

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

Secondary outcomes

  1. Clinical failure

    Defined as the absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  2. Serious Adverse Event or Adverse Event Leading to Discontinuation

    Defined as a serious adverse drug event (Common Terminology Criteria for Adverse Events (CTCAE) class 4) presumed due to study drug OR adverse drug event (CTCAE classes 1-3) leading to discontinuation of the study drug

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  3. All cause mortality

    Death from any cause

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  4. Infectious Complications

    Defined as change in therapy for inadequate clinical response; new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of MRSA bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures; change of antibiotic therapy due to inadequate clinical response. New implies that the complication was not suspected at enrollment and is not a function of delay to diagnostic testing.

    Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)

  5. Drug Induced Myostitis

    Defined as a creatinine kinase level greater than or equal to 5 times the upper limit of normal

    Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)

  6. Eosinophilic pneumonia

    Defined as the development of symptomatic eosinophilic pneumonia as diagnosed by the treating team in consultation with the appropriate specialists

    Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)

07

Study locations

20 of 20 sites recruiting
08

References and documents

Publications

  • Zhang G, Zhang N, Xu J, Yang T, Yin H, Cai Y. Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Int J Antimicrob Agents. 2023 Oct;62(4):106946. doi: 10.1016/j.ijantimicag.2023.106946. Epub 2023 Aug 4. PubMed 37543121 ↗
  • Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653-65. doi: 10.1056/NEJMoa053783. PubMed 16914701 ↗

Individual participant data

Plan to share: Undecided — Data sharing policies are dependent on the policies of the SNAP Platform (NCT05137119)

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Jan 2029
CompletionEst.
Nov 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06637332
Lead sponsor
Todd C. Lee MD MPH FIDSA
Collaborators
University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Responsible party
Todd C. Lee MD MPH FIDSA (Associate Professor of Medicine, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Sponsor-investigator
First posted
Oct 15, 2024
Start date
Nov 14, 2024
Primary completion
Jan 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

Lina Petrella
Contact
lina.petrella@muhc.mcgill.ca
514-934-1934 ext. 23730
Todd C Lee, MD MPH FIDSA
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daptomycin

Start the discussion